海翔药业
(002099)
| 流通市值：93.85亿 | | | 总市值：94.05亿 |
| 流通股本：16.15亿 | | | 总股本：16.19亿 |
| 报告期 | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 |
| 公司类型 | 通用 | 通用 | 通用 | 通用 |
| 一、营业总收入 | 486,496,687.33 | 1,860,693,572.54 | 1,366,585,897.97 | 925,159,120.06 |
| 营业收入 | 486,496,687.33 | 1,860,693,572.54 | 1,366,585,897.97 | 925,159,120.06 |
| 二、营业总成本 | 494,767,487.53 | 1,897,235,398.52 | 1,336,577,933.58 | 892,850,523.47 |
| 营业成本 | 354,451,154.54 | 1,405,933,999.83 | 1,011,609,724.9 | 683,418,968.06 |
| 税金及附加 | 7,767,988.11 | 33,156,531.03 | 23,894,235.87 | 16,850,848.62 |
| 销售费用 | 6,033,291.39 | 28,676,824.28 | 16,299,756.66 | 9,629,893.03 |
| 管理费用 | 76,547,726.94 | 308,287,485.79 | 204,657,731.9 | 133,331,324.74 |
| 研发费用 | 28,208,897.8 | 116,933,717.28 | 89,597,094.85 | 61,498,851.33 |
| 财务费用 | 21,758,428.75 | 4,246,840.31 | -9,480,610.6 | -11,879,362.31 |
| 其中:利息费用 | 6,157,198.02 | 27,250,265.25 | 20,594,251.7 | 15,041,971.59 |
| 其中:利息收入 | 5,499,572.17 | 50,776,763.03 | 39,458,345.59 | 25,536,249.53 |
| 三、其他经营收益 | | | | |
| 加:公允价值变动收益 | 1,130,733.24 | -14,790,765.56 | -387,129.53 | 6,903,972.57 |
| 加:投资收益 | 65,925,117.72 | 55,647,202.13 | 10,188,242.89 | -3,170,711.71 |
| 资产处置收益 | 128,524.45 | 31,936.39 | -12,910.75 | -26,079.94 |
| 资产减值损失(新) | -35,415,258.35 | -102,558,171.1 | -28,435,486.51 | -21,385,830.75 |
| 信用减值损失(新) | -1,580,035.42 | -2,824,178.31 | -2,250,828.97 | -1,317,707.28 |
| 其他收益 | 3,540,940.18 | 21,010,096.6 | 15,028,586.96 | 11,468,536.32 |
| 四、营业利润 | 25,459,221.62 | -80,025,705.83 | 24,138,438.48 | 24,780,775.8 |
| 加:营业外收入 | 1,247,127.9 | 5,682,418.28 | 3,792,433.98 | 2,009,256.5 |
| 减:营业外支出 | 592,916.33 | 9,747,736.73 | 9,346,876.6 | 7,494,738.2 |
| 五、利润总额 | 26,113,433.19 | -84,091,024.28 | 18,583,995.86 | 19,295,294.1 |
| 减:所得税费用 | -189,410.07 | 9,663,346 | 13,546,896.64 | 6,672,088.17 |
| 六、净利润 | 26,302,843.26 | -93,754,370.28 | 5,037,099.22 | 12,623,205.93 |
| (一)按经营持续性分类 | | | | |
| 持续经营净利润 | 26,302,843.26 | -93,754,370.28 | 5,037,099.22 | 12,623,205.93 |
| (二)按所有权归属分类 | | | | |
| 归属于母公司股东的净利润 | 26,446,414.59 | -91,075,551.15 | 7,290,271.47 | 14,093,711.9 |
| 少数股东损益 | -143,571.33 | -2,678,819.13 | -2,253,172.25 | -1,470,505.97 |
| 扣除非经常损益后的净利润 | -43,244,768.17 | -136,616,197.47 | 5,010,483.28 | 19,283,282.22 |
| 七、每股收益 | | | | |
| (一)基本每股收益 | 0.02 | -0.06 | 0 | 0.01 |
| (二)稀释每股收益 | 0.02 | -0.06 | 0 | 0.01 |
| 八、其他综合收益 | - | 14,373,444.92 | - | - |
| 归属于母公司股东的其他综合收益 | - | 14,373,444.92 | - | - |
| 九、综合收益总额 | 26,302,843.26 | -79,380,925.36 | 5,037,099.22 | 12,623,205.93 |
| 归属于母公司股东的综合收益总额 | 26,446,414.59 | -76,702,106.23 | 7,290,271.47 | 14,093,711.9 |
| 归属于少数股东的综合收益总额 | -143,571.33 | -2,678,819.13 | -2,253,172.25 | -1,470,505.97 |
| 公告日期 | 2026-04-29 | 2026-04-29 | 2025-10-29 | 2025-08-30 |
| 审计意见(境内) | | 标准无保留意见 | | |